therapeutics to improve cardiovascular health
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA approved product and is available in the United States by prescription. For more information about Vascepa visit www.vascepa.com.
21 Mar 2017
Amarin Corporation CEO, John Thero, to Chair the American Heart Association's Heart & Stroke Ball in New York City MORE
16 Mar 2017
Amarin Reaches the Onset of Approximately 80% of the Target Aggregate Number of Primary Major Adverse Cardiovascular Events Within the REDUCE-IT Study MORE
- AMRN (NASDAQ)
- Thu, 23 Mar 2017 09:38
Join Our Mailing List
You may automatically receive Amarin Corporation plc financial information by email.